| Name | Eden Research |
|---|---|
| Epic | EDEN |
| Isin | GB0001646941 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 4.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £21.33 | Debt ratio | n/a |
| Shares in issue | 533.35 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -94.78 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.59 | 52-week high / low | 3.90p / 6.25p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Eden Research |
|---|---|
| Address | 67C Innovation Drive, Milton Park, Abingdon, Oxfordshire, England, United Kingdom, OX14 4RQ |
| Telephone | |
| Website | http://www.edenresearch.com/ |
| Director | Position |
|---|---|
| Mr Sean M. Smith | CEO |
| Mr Alexander John Abrey | CFO |
| Mr Derek McAllan | Non-Executive Director |
| Mr Robin James Scott Cridland | Non-Executive Director |
| Mr Lykele van der Broek | Non-Executive Chairman |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 8.45 | 7.92 | 6.73 |
| Investments and other non-current assets | 0.33 | 0.36 | 0.42 |
| Total non-current assets | 9.31 | 8.89 | 7.73 |
| Inventory / work in progress | 0.63 | 0.52 | 0.22 |
| Trade and other receivables | 0.66 | 0.89 | 1.4 |
| Cash and equivalents | 1.99 | 3.83 | 7.29 |
| Other current assets and asset held for resale | 0.32 | 0.9 | 0.29 |
| Total of all assets | 12.91 | 15.03 | 16.92 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 1.95 | 1.81 | 1.54 |
| Long term liabilities | 0.22 | 0.39 | 0.46 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 2.17 | 2.2 | 2 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 10.78 | 12.83 | 14.93 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 3.81 | 3.8 | 3.8 |
| Minority interests | n/a | n/a | 0.02 |
| Retained earnings | -43.25 | -41.41 | -38.84 |
| Share premium account | 39.31 | 39.31 | 39.31 |
| Total equity | 10.78 | 12.83 | 14.93 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.57 | -3.21 | -2.24 |
| Pre-tax profit | -2.57 | -3.4 | -2.55 |